NEO stock forecast
Our latest prediction for NeoGenomics, Inc.'s stock price was made on the Nov. 19, 2019 when the stock price was at 24.22$.
In the short term (2weeks), NEO's stock price should outperform the market by 0.20%. During that period the price should oscillate between -5.94% and +5.83%.
In the medium term (3months), NEO's stock price should outperform the market by 1.83%. During that period the price should oscillate between -14.40% and +17.93%.Get email alerts
Create a solid portfolio with NEO
About NeoGenomics, Inc.
NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
At the moment the company generates 378M USD in revenues.
On its last earning announcement, the company reported a profit of 0.02$ per share.
The book value per share is 2.00$
Three months stock forecastNov. 19, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|